Free Triiodothyronine and Free Triiodothyronine to Free Thyroxine Ratio Predict All-Cause Mortality in Patients with Diabetic Foot Ulcers. 2022

Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China.

OBJECTIVE Free triiodothyronine (FT3) and FT3/free thyroxine (FT4) ratio have been associated with mortality in various diseases. However, no study to date has identified a link between FT3, FT3/FT4 ratio and all-cause mortality in patients with diabetic foot ulcers (DFUs). This study aimed to investigate this relationship. METHODS This retrospective cohort study included 726 patients diagnosed with DFUs in a public hospital from January 2015 to October 2019. Patients were classified by the optimal cut-off values of the FT3 and FT3/FT4 ratio, respectively. The association of FT3 and FT3/FT4 ratio with all-cause mortality was evaluated in a multivariable cox regression model. Directed acyclic graphs were used to assess the minimally sufficient sets of confounding variables. RESULTS Log rank tests indicated that patients with low FT3 and FT3/FT4 ratio had lower overall survival rates (all p < 0.001). The adjusted HRs for all-cause mortality were 0.48 (95% CI: 0.32-0.73, P = 0.001) when comparing high versus low FT3 and 0.47 (95% CI: 0.32-0.70, P < 0.001) when comparing high versus low FT3/FT4 ratio. Subgroup analyses showed that these associations existed only in elderly patients (≥65 years) and women, after adjustment. In men, only high FT3/FT4 ratio was associated with low all-cause mortality, after adjustment. CONCLUSIONS Routine assessment of FT3 and FT3/FT4 ratio may be a simple and effective way to identify high-risk patients with DFUs, especially in elderly patients and women.

UI MeSH Term Description Entries

Related Publications

Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
January 2016, PloS one,
Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
February 2022, Diabetes/metabolism research and reviews,
Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
January 2018, International journal of endocrinology,
Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
January 2023, Frontiers in nutrition,
Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
July 2022, Endocrine connections,
Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
January 2005, European journal of heart failure,
Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
January 2008, Journal of the American Podiatric Medical Association,
Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
January 2023, Journal of diabetes investigation,
Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
January 2018, Diabetes & metabolic syndrome,
Jing Hong, and Wen-Yue Liu, and Xiang Hu, and Wen-Wen Chen, and Fei-Fei Jiang, and Ze-Ru Xu, and Fei-Xia Shen, and Hong Zhu
June 2023, Zhonghua yi xue za zhi,
Copied contents to your clipboard!